Showing results (1-10 of 433) with videos related to
Sort By:
Pageof 44
Inflammatory Bowel Diseases|December 23, 2017
A Survey Study of Gastroenterologists' Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel DiseaseLaurie B Grossberg, Konstantinos Papamichael, Joseph D Feuerstein, et al.Mayo Clinic Proceedings|June 12, 2017
Crohn Disease: Epidemiology, Diagnosis, and ManagementJoseph D Feuerstein, Adam S CheifetzGastroenterology Clinics of North America|August 12, 2014
Miscellaneous adverse events with biologic agents (excludes infection and malignancy)Joseph D Feuerstein, Adam S CheifetzMayo Clinic Proceedings|September 10, 2014
Ulcerative colitis: epidemiology, diagnosis, and managementJoseph D Feuerstein, Adam S CheifetzGastroenterology Clinics of North America|April 17, 2012
Patient-specific approach to combination versus monotherapy with the use of antitumor necrosis factor α agents for inflammatory bowel diseaseShane M Devlin, Adam S Cheifetz, Corey A Siegel, et al.Journal of Medical Systems|July 23, 2016
How to Develop the Medical NeighborhoodJoseph D Feuerstein, Victoria Sheppard, Adam S Cheifetz, et al.Annals of Gastroenterology|July 2, 2016
Systematic review and meta-analysis of third-line salvage therapy with infliximab or cyclosporine in severe ulcerative colitisJoseph D Feuerstein, Mona Akbari, Elliot B Tapper, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 10, 2020
Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel DiseasesKonstantinos Papamichael, William T Clarke, Niels Vande Casteele, et al.Seminars in Arthritis and Rheumatism|November 3, 2015
Systematic analysis of the quality of the scientific evidence and conflicts of interest in osteoarthritis of the hip and knee practice guidelinesJoseph D Feuerstein, Jonathan R Pelsis, Samuel Lloyd, et al.Clinical Immunology (Orlando, Fla.)|March 31, 2018
Patients with core antibody positive and surface antigen negative Hepatitis B (anti-HBc+, HBsAg-) on anti-TNF therapy have a low rate of reactivationWilliam T Clarke, Shreya S Amin, Konstantinos Papamichael, et al.Pageof 44